"Major depressive disorder (MDD) affects over 280 million people worldwide and represents a leading cause of disability. Due to the advance of a wide range of psychiatric drugs and psychotherapies, about 60 to 70 percent of patients improve. The remaining 30 percent of patients do not respond to several trials of drugs and psychotherapy. Their illnesses drag on like long Covid. Theyare said to suffer from treatment-resistant depressions (TRD) and treatment-resistant schizophrenias (TRS)."
"Ketamine as an anesthetic was introduced in the 1970s, both in Canada and the U.S. Since then, driven by research into ketamine's effectiveness for treatment-resistant depression and other mental health conditions, ketamine clinics have been rapidly expanding across the U.S. and Canada. Ketamine may be administered intravenously, intranasally ( esketamine), or orally. Multiple recent randomized controlled trials (RCTs) and observational studies confirmed rapid antidepressant and antisuicidal effects (hours to days) of all forms of ketamine, while adverse events were mild and transient."
Major depressive disorder affects over 280 million people worldwide and is a leading cause of disability. About 60 to 70 percent of patients improve with psychiatric drugs and psychotherapies. Approximately 30 percent fail to respond to multiple trials of drugs and psychotherapy and are classified as having treatment-resistant depression or schizophrenia. Alternative treatment options for these refractory cases include anesthetics such as ketamine, psychedelics such as psilocybin, electroconvulsive therapy, and various forms of electrical brain stimulation. Ketamine has shown rapid antidepressant and antisuicidal effects in randomized trials and observational studies, with usually mild, transient adverse events.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]